obesity drug news today glp-1 october 2025 Chart: 1 in 8 Americans Now Use Drugs for Weight Loss obesity drug news today glp-1

however, their use is limited due to the development of intolerable anticholinergic adverse events, including confusion, drowsiness, memory impairment, dry mouth, constipation, and visual changes

3 mg/mL concentration Less common but still encountered, particularly in some compounded preparations

Gastrointestinal side effects remain among the most frequently cited challenges associated with currently marketed GLP-1 therapies and represent a significant driver of discontinuation

however, it piqued significant public and commercial interest in 2021 when the STEP-1 trial demonstrated up to 14% placebo-adjusted weight loss, leading to its approval as a weight loss drug, Wegovy

3d), suggesting a divergent mechanism from hGIP in alpha cells

Her examination in the office was notable for Grade I papilledema of the optic discs